Journal
CANCER LETTERS
Volume 451, Issue -, Pages 122-127Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.03.003
Keywords
Undifferentiated soft-tissue sarcoma; Olaratumab; Doxorubicin; Ifosfamide; PDGFR-alpha; Patient-derived orthotopic xenograft; Combination therapy
Categories
Ask authors/readers for more resources
Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFR alpha), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy. The goal of the present study was to determine the efficacy of OLA in combination with DOX and ifosfamide (IFO) on STS. Undifferentiated soft-tissue sarcoma (USTS) from a striated muscle of a patient was grown orthotopically in the right biceps femoris muscle of nude mice to establish USTS patient-derived orthotopic xenograft (PDOX) model. USTS PDOX tumors were treated with OLA alone, DOX alone, DOX combined with IFO, OLA combined with DOX or IFO, and OLA combined with DOX and IFO. Tumor size and body weight were measured during the 14 days of treatment. Tumor growth was arrested by OLA combined with DOX and IFO. Tumors treated with OLA combined with DOX and IFO had the most necrosis. The present study demonstrates the power of the PDOX model to identify the novel effective treatment strategy of the combination of OLA, DOX and IFO for soft-tissue sarcomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available